EMA/587280/2013

European Medicines Agency decision

P/0248/2013

of 10 October 2013

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for sofosbuvir / ledipasvir (EMEA-001411-PIP01-12) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This Decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom
Telephone +44 (0)20 7418 8400 **Facsimile** +44 (0)20 7523 7040
E-mail info@ema.europa.eu **Website** www.ema.europa.eu
An agency of the European Union

European Medicines Agency decision

P/0248/2013

of 10 October 2013

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for sofosbuvir / ledipasvir (EMEA-001411-PIP01-12) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency[2],

Having regard to the application submitted by Gilead Sciences International Ltd. on 14 February 2013 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 13 September 2013, in accordance with Article 18 of Regulation (EC) No 1901/2006, and Article 21 of said Regulation and Article 13 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver.

(2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.

(3) It is therefore appropriate to adopt a decision granting a deferral.

(4) It is therefore appropriate to adopt a decision granting a waiver.

[1] OJ L 378, 27.12.2006, p.1.
[2] OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

A paediatric investigation plan for sofosbuvir / ledipasvir, age-appropriate dosage form, other age-appropriate oral solid dosage form, film-coated tablet, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

A deferral for sofosbuvir / ledipasvir, age-appropriate dosage form, other age-appropriate oral solid dosage form, film-coated tablet, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

A waiver for sofosbuvir / ledipasvir, age-appropriate dosage form, other age-appropriate oral solid dosage form, film-coated tablet, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 4

This decision is addressed to Gilead Sciences International Ltd., Flowers Building, Granta Park, Abington, CB21 6GT, - Cambridge, United Kingdom.

Done at London, 10 October 2013

For the European Medicines Agency
Guido Rasi
Executive Director
(Signature on file)

EMA/PDCO/389816/2013

Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a deferral and a waiver

EMEA-001411-PIP01-12

Scope of the application

Active substance(s):

Sofosbuvir / ledipasvir

Condition(s):

Treatment of chronic hepatitis C

Pharmaceutical form(s):

Age-appropriate dosage form, other

Age-appropriate oral solid dosage form

Film-coated tablet

Route(s) of administration:

Oral use

Name/corporate name of the PIP applicant:

Gilead Sciences International Ltd.

Basis for opinion

Pursuant to Article 11 of Regulation (EC) No 1901/2006 as amended, Gilead Sciences International Ltd. submitted for agreement to the European Medicines Agency on 14 February 2013 an application for a paediatric investigation plan for the above mentioned medicinal product and a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation.

The procedure started on 20 March 2013.

Supplementary information was provided by the applicant on 21 June 2013. The applicant proposed modifications to the paediatric investigation plan.

7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom
Telephone +44 (0)20 7418 8400 **Facsimile** +44 (0)20 7523 7040
E-mail info@ema.europa.eu **Website** www.ema.europa.eu
An agency of the European Union

Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree the paediatric investigation plan in accordance with Article 18 of said Regulation;
   - to grant a deferral in accordance with Article 21 of said Regulation;
   - to grant a waiver for one or more subsets of the paediatric population in accordance with Article 13 of said Regulation and concluded in accordance with Article 11(1)(c) of said Regulation, on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments for paediatric patients.

   The Icelandic and the Norwegian Paediatric Committee members agree with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

London, 13 September 2013

On behalf of the Paediatric Committee
Dr Dirk Mentzer, Chairman
(Signature on file)

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed Paediatric Investigation Plan

1. Waiver

1.1. Condition: Treatment of chronic hepatitis C

The waiver applies to:

- The paediatric population from birth to less than 3 years of age;
- for film-coated tablet, alternative solid formulation, and age-appropriate paediatric formulation, oral use;
- on the grounds that clinical studies with the specific medicinal product cannot be expected to be of significant therapeutic benefit to or fulfil a therapeutic need of the specified paediatric subset(s).

2. Paediatric Investigation Plan

2.1. Condition: Treatment of chronic hepatitis C

2.1.1. Indication(s) targeted by the PIP

Sofosbuvir (SOF)/ledipasvir (LDV) fixed dose combination (FDC) is indicated for the treatment of children 3 to less than 18 years of age with chronic hepatitis C.

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 3 to less than 18 years of age.

2.1.3. Pharmaceutical form(s)

Age-appropriate dosage form, other

Age-appropriate oral solid dosage form

Film-coated tablet

2.1.4. Measures

Area	Number of measures	Description
Quality	2	Measure 1: Development of alternative age-appropriate oral solid dosage form for children 6 to less than 12 years of age and adolescents unable to swallow the adult tablet Measure 2: Development of age-appropriate dosage form for children 3 to less than 6 years of age
Non-clinical	0	Not applicable.
Clinical	2	Measure 3: Randomized, open-label, 2-period crossover, single-dose study in healthy adults to assess relative bioavailability and safety of age-appropriate paediatric formulation of sofosbuvir (SOF)/ledipasvir (LDV) fixed dose

Area	Number of measures	Description
		combination (FDC) versus adult formulation Measure 4: Open-label, single-arm study to investigate safety and efficacy of sofosbuvir (SOF)/ledipasvir (LDV) fixed-dose combination (FDC) for 12 weeks in adolescents and children with chronic genotype 1-6 HCV infection

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety and efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By June 2018
Deferral for one or more measures contained in the paediatric investigation plan:	Yes